BiotechTube
Clinartis

Clinartis

San Francisco, United States· Est.
clinartis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Clinartis is a private, service-oriented digital health company founded in 2015, headquartered in San Francisco. It operates as a full-service Contract Research Organization (CRO), supporting sponsors in executing clinical trials from early-stage (Phase 1) through later phases. The company differentiates itself through a personalized, 'one-stop' service model aimed at reducing sponsor burden and emphasizes expertise in complex early-stage studies, including first-in-human, SAD/MAD, and special population trials. Its financial position is likely supported by service contracts, placing it in a revenue-generating stage.

Digital Health

Technology Platform

Integrated clinical trial service offering and operational methodology, leveraging expertise in project management, data management, regulatory affairs, and specialized early-phase trial design. Relies on standard industry tools (EDC, CTMS) rather than a proprietary technology platform.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The growing trend of biopharma outsourcing and increasing complexity of early-stage trials, especially in niche areas like studies in special populations, creates demand for specialized CRO services.
Small to mid-sized biotechs, which are prolific innovators, represent a key client segment seeking the personalized, hands-on approach Clinartis emphasizes.

Risk Factors

High competition from both large global CROs and other niche providers pressures pricing and client acquisition.
Revenue is directly tied to client R&D budgets, which are sensitive to biotech funding cycles.
Reputational damage from any significant trial execution failure could be catastrophic in this service-based model.

Competitive Landscape

Clinartis operates in the highly fragmented and competitive global CRO market. It competes with large, full-service CROs (e.g., IQVIA, Labcorp, ICON) on service breadth and with numerous small-to-midsized CROs on agility and cost. Its differentiation is based on a personalized service model and advertised expertise in complex early-phase clinical development.

More companies in Digital Health & Biotech SaaS →More companies in United States →